<table class="naaccr-summary-table naaccr-borders">
    <tr>
        <th class="naaccr-summary-header naaccr-borders">Item #</th>
        <th class="naaccr-summary-header naaccr-borders">Length</th>
        <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
        <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
    </tr>
    <tr>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">3855</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">NAACCR</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2018</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">18</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.her2OverallSummary<br/><br/>


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div>
<div class='content chap10-para'>HER2 Overall Summary is a summary of results from HER2 testing.</div>
<div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div>
<div class='content chap10-para mark-changed'>
    <div>This data item is required for prognostic stage grouping in AJCC 8th edition, Chapter 48,


        <em>Breast</em>. It was previously collected as Breast, CS SSF # 15.Experts recommend that every invasive breast cancer be tested for the presence of HER2 because anti-HER2 treatments are highly effective for these tumors.
    </div>
    <div>&nbsp;</div>
    HER2 overall summary will be collected for Esophagus and Esophagogastric Junction and Stomach for cases diagnosed 1/1/21+ because NCCN guidelines recommend HER2 testing at time of diagnosis if patients are documented or suspected of having metastatic disease. HER2 monoclonal antibodies may be added to chemotherapy for patients with HER2 positive disease.
</div>
<div class='content chap10-para'><strong>Codes</strong></div>
<div class='content chap10-para mark-changed'>
    <table>
        <tr class='code-row'>
            <td class='code-nbr'>0</td>
            <td class='code-desc'>HER2 negative; equivocal</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>1</td>
            <td class='code-desc'>HER2 positive</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>7</td>
            <td class='code-desc'>Test ordered, results not in chart</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>8</td>
            <td class='code-desc'>Not applicable: Information not collected for this case<br/>
                (If this item is required by your standard setter, use of code 8 will result in an edit error.)
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>9</td>
            <td class='code-desc'>Not documented in medical record<br/>
                Cannot be determined (indeterminate)<br/>
                HER2 Overall Summary status not assessed or unknown if assessed
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'></td>
            <td class='code-desc'></td>
        </tr>
    </table>
</div>
<div class='content chap10-para'>Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.</div>